Dow Jones 9809.86 +23.25 10:00 am PST, October 31, 2003  NASDAQ 1931.84 -0.85 For info, visit access.smallcapnetwork.com S & P 500 1050.61 +3.67 To be removed, please click here Russell 2000 529.43 -0.94 VOLUME 03: ISSUE 67  BioCurex: Unparalleled Cancer Detection, Assure Energy Update and Preferred Member Opportunity Cancer markers are molecules that distinguish cancerous cells from normal cells. Never has there been a universal marker identified that appears in all types of cancer thereby enabling early detection. Hence, there are no universal blood or tissue tests that can detect all forms of cancer through a single marker. Until now. BioCurex (OTCBB: BOCX) has identified and patented a universal marker, named RECAF, found to be present in all forms of cancer cells studied, including-- but not limited to -- those of the breast, lung, prostate and the gastrointestinal system. One third of all cancers are breast or lung specific. In the last 40 years, only a half dozen cancer markers have been found and none have the universality of the RECAF marker: Rather, these are condition specific--PSA for prostate cancer and CEA for colorectal cancer, to name two. Further, BioCurex has developed proprietary tissue and blood tests to detect the RECAF marker in virtually all cancers--both early and late stage-- with an unparalleled sensitivity and specificity rate averaging 95 percent. As well, BOCX has secured the US patent for the RECAF marker and has patents pending in no fewer than 22 other countries. (If you missed our Trading Alert last Friday, click here).  Huge Markets, Huge Potential The US market alone for pathology, blood tests, imaging, antibody therapy and cancer vaccines is in the range of $8-$10 billion and, unfortunately, growing. Globally, those numbers triple. BioCurex is in excellent position to attain a large portion of those markets. Even a 2 percent market share would translate into $200 million in revenue. There are currently 23 million shares of BOCX outstanding giving the biotech company a market capitalization of $5 million. We feel strongly that risk tolerant investors should consider accumulating BioCurex at these levels. BioCurex presently has no revenues and funds itself by private investment-- not unusual by early stage biotech norms. Current cash on hand and low monthly administrative costs should easily see the company through to its goal of securing its first, and subsequent, license agreements. The next phase is to realize profits through the securing of large license agreements with some of the most influential medical supply/testing companies in the world. How it works By way of illustration, let's examine the power of BioCurex's technology on the detection of breast cancer. By examining this facet of the disease--breast cancer accounts for 15 percent of cancers--investors will be able to extrapolate the company's massive potential across the entire cancer diagnosis and therapy spectrum. Breast tissue samples stained with our kits.(1) Cancer cells are always stained in brown, whereas normal cells appear in gray/blue. (2) Needle biopsy of breast cancer. Malignant cells are brown. (3) Needle biopsy of a benign breast tumor. Benign cells are not brown. (4) Frozen section stained with Cryo-RECAFTM: Cancer cells are brown, normal surrounding cells are blue. When breast cancer tissue is tested for the presence of the RECAF marker using BioCurex's proprietary (and FDA cleared) Histo-RECAF test, it has a sensitivity (detection rate) of 100 percent and high specificity (occurrence of false positives) of a very low 4 percent-- both determined in independent studies.  For other types of cancer, BioCurex's blood and tissue tests' sensitivity and specificity average 90 percent. The following chart measures sensitivity statistics (BOCX's 'RECAF' at the bottom) against other tests currently on the market. Beyond initial early stage diagnosis, there is the added benefit of using BioCurex's products for ongoing tissue/blood testing against the recurrence of cancer--evidencing the potential for a significant ongoing royalty revenue stream. The benefits to patients, and the healthcare system, as well as lower costs for all involved, are significant.  When a new or recurring cancer can be detected through a drop of blood or a needle biopsy rather than subjective or less effective tests, or expensive invasive procedures, the timing of these products is certainly propitious for patients, BioCurex and its investors. Not even close The closest 'competitors' to BioCurex for breast cancer markers are prognosis products that identify the Herceptin molecules which occurs in roughly 25 percent of healthy women with a family history of the disease. The sales of Herceptin marker prognosis products went from $0- $300 million in 3-5 years. Since BioCurex is obviously superior as it is a marker detector  with superior  specificity, the company intends to capture a significant --25 percent within three years-- part of the breast cancer detection and diagnosis market (currently $200 million annually) as well as that for other cancers. BioCurex presently has three products: Histo-,Serum-, and Cryo-RECAF. Histo and Cryo are for tissue tests, Serum for blood tests. Continuing with our delineation of the efficacy of RECAF detection, consider this hypothetical a scenario. A patient is on the operating table and the surgeon has found a breast tumor or suspect tissue. Currently, the pathologist needs to test that tissue to determine whether it's malignant. By applying BioCurex's Cryo-RECAF test, the tissue is flash frozen, sliced and stained. The surgeon gets an answer inside fifteen minutes and can move ahead accordingly. In the case of breast cancer, both the breast biopsy as well as a lymph node sample can be tested to discover if there is metastasis (spreading) of the cancer. The obvious benefits, over the low test cost and reduced time taken for detection, is that the patient can stay under anaesthetic and the entire healthcare system saves precious time and money while delivering timely, effective patient care.  Where do we go from here? How big are the markets for these types of tests? And how does BioCurex plan to profit? It is difficult to estimate the market size for BioCurex's RECAF tests and therapies because there are no comparable products in the marketplace. With its near perfect sensitivity and specificity for finding virtually all types of cancer, either through tissue or blood tests, low kit cost and ease of use, BioCurex not only represents a compelling speculative investment, but could well revolutionize the way cancer is detected and treated. BioCurex intends to seek non-exclusive license agreements for its products through the world's largest medical supply/testing companies. Currently in discussions with nine companies--most of which are household names--the company intends to secure multiple licenses over the next 12 months. The corporate strategy is to secure a significant fee up-front as well as ongoing royalty arrangements in the neighborhood of between 10-20 percent for each product licensed. Given the size of the testing markets, even in the US alone, the growth potential is extraordinary. By securing non-exclusive licenses, BioCurex would have no need to set up capital draining sales, marketing or manufacturing divisions: the licensees, by virtue of their own well-established global infrastructures internal quality control systems would handle the production and distribution.  The Bottom Line. BioCurex has already been in contact with the major players and has signed the appropriate documents to allow potential licensees the ability to validate the company's claims. BioCurex is developing other products based on the RECAF marker. It will soon engage promising research into a cancer vaccine--anti-RECAF--that would mobilize antibodies [to home in only on cancer cells] to protect against most kinds of cancer. While owning the stock ahead of the first licensing agreement is riskier, we believe that this affords investors the greatest upside potential. There's lots more. We'll bring it all to you as it unfolds. SmallCap Digest will be all over this very exciting company and its technology.   MARKET NOTE/FOLLOW UP Assure Energy (OTCBB: ASUR) is gaining steam this week as volume surged--just under 1 million shares for the week--as the shares rose to an all time high of $4.60, Thursday. That denotes a return of 21 percent since our Trading Alert on September 27th. Chart action looks good as investors are seeing lower lows on pullbacks and higher highs on upside moves.  There's more news to come on Assure as its drilling program picks up and the natural gas crisis looms. We'll bring you a further update soon, but as we have mentioned, Assure should have a place in the long-term resource portion of your portfolio. Stay tuned. ABOUT ASSURE ENERGY, INC.: Assure Energy, Inc. (Assure) is a junior oil and gas exploration and production company that operates through its wholly owned subsidiary, Assure Oil and Gas Corp., and its subsidiary Westerra 2000 Inc. Assure oil and gas properties are focussed in the Western Canadian Sedimentary Basin. Through Assure Holdings Limited, the Company also owns approximately 48.5% of Quarry Oil and Gas Ltd., an Alberta based junior oil and gas exploration and production company.   Take Advantage of a Special Opportunity. Get on Board our new Preferred Member List NOW while it's FREE! SmallCap Digest continues to get better and yes of course, it's still FREE. Our readers have continued to express an interest in having the SmallCap Digest develop a Preferred Member List Program. We've listened to all of your suggestions and now is your opportunity to take advantage of this new program. Here's what you could start receiving. Sign-up instructions are shown below. Receive the SmallCap Digest ahead of the pack prior to general delivery. Be eligible for unique, specialized content and trading alerts not generally distributed to regular readers. Have a specialized 'Preferred' email address to send us analysis questions and market inquiries. Numerous other features in development to be announced over the coming months. NOW, simply opt-in your email address, confirm the request for confirmation you will receive in your inbox and you'll be in position to start receiving these new special features available only to Preferred Members! DO NOT GET LEFT BEHIND! To subscribe to the preferred member list, simply click here. Or, to subscribe by email, send a blank email to scn-preferred-subscribe@delta.levelogic.com. If there is a problem with the subscription or you do not receive a confirmation email within 2 hours, go to http://access.smallcapnetwork.com/pref-sub.html and submit your email address.   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Additionally, TGR Group LLC has been paid a fee by Assure Energy of $25,000 and 100,000 warrants, exercisable at $3 into restricted shares of Assure, for publishing on the company for a period of one year. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.